The San Antonio Breast Cancer Symposium
- 1 February 2011
- journal article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 11 (1), 10-14
- https://doi.org/10.3816/cbc.2011.n.002
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2010
- Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST StudyAnnals of Oncology, 2010
- Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialThe Lancet Oncology, 2009
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJournal of Clinical Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerThe New England Journal of Medicine, 2009
- The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response – exploratory evidence for direct anti-tumor activity in breast cancer.Cancer Research, 2009
- Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized TrialJournal of Clinical Oncology, 2004
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal womenCancer, 2003
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002